Want to see HK:2268 full AI Analyst Report?
2268 Stock Chart & Stats
HK$75.50
-HK$0.65(-1.20%)
At close: 4:00 PM EDT
HK$75.50
-HK$0.65(-1.20%)
Day’s Range― - ―
52-Week RangeHK$43.50 - HK$85.50
Previous CloseN/A
Volume2.89M
Average Volume (3M)9.78M
Market Cap
HK$100.89B
Enterprise ValueHK$72.45K
Total Cash (Recent Filing)HK$5.73B
Total Debt (Recent Filing)HK$531.43M
Price to Earnings (P/E)56.8
Beta0.97
Next Earnings
Mar 29, 2027EPS Estimate
0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.22
Shares Outstanding1,268,295,800
10 Day Avg. Volume4,803,686
30 Day Avg. Volume9,784,626
Financial Highlights & Ratios
PEG Ratio1.21
Price to Book (P/B)6.72
Price to Sales (P/S)12.13
P/FCF Ratio113.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$91.06Price Target Upside20.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)1.52
Revenue Forecast (FY)HK$8.16B
Bulls Say, Bears Say
Bulls Say
Strong Interim Growth And ProfitabilityRapid revenue expansion alongside higher gross margins and stable adjusted net margins indicates strong demand for the company’s services and operating leverage that can support earnings over the next several months.
Conservative Balance SheetVery low leverage limits interest and refinancing risk, giving WuXi XDC financial flexibility to fund capacity expansion, absorb industry volatility, and pursue growth without relying heavily on external borrowing.
Integrated Outsourced Biopharma ServicesAn integrated fee-for-service model can deepen customer relationships and support projects moving from development into manufacturing, potentially increasing contract duration, project scale, and recurring demand for specialized capabilities.
Bears Say
Weak And Volatile Free Cash FlowUneven free cash flow and weak conversion of accounting profit suggest substantial reinvestment or working-capital needs. This may constrain discretionary cash available for expansion, dividends, or other shareholder returns.
Historical Margin CompressionAlthough recent interim margins improved, prior compression shows that scaling the platform can raise cost intensity. Sustaining profitability will depend on continued utilization gains, pricing discipline, and operating efficiency.
Ongoing Equity-Based CompensationLong-term equity incentives may help retain specialized talent, but recurring share grants can increase dilution and compensation costs. Their value to shareholders depends on whether stronger execution offsets the expanding equity base.
WuXi XDC Cayman, Inc. News
2268 FAQ
What was WuXi XDC Cayman, Inc.’s price range in the past 12 months?
WuXi XDC Cayman, Inc. lowest stock price was HK$43.50 and its highest was HK$85.50 in the past 12 months.
What is WuXi XDC Cayman, Inc.’s market cap?
WuXi XDC Cayman, Inc.’s market cap is HK$100.89B.
When is WuXi XDC Cayman, Inc.’s upcoming earnings report date?
WuXi XDC Cayman, Inc.’s upcoming earnings report date is Mar 29, 2027 which is in 184 days.
How were WuXi XDC Cayman, Inc.’s earnings last quarter?
WuXi XDC Cayman, Inc. released its earnings results on Aug 24, 2026. The company reported HK$0.701 earnings per share for the quarter, missing the consensus estimate of HK$0.806 by -HK$0.105.
Is WuXi XDC Cayman, Inc. overvalued?
According to Wall Street analysts WuXi XDC Cayman, Inc.’s price is currently Undervalued.
Does WuXi XDC Cayman, Inc. pay dividends?
WuXi XDC Cayman, Inc. does not currently pay dividends.
What is WuXi XDC Cayman, Inc.’s EPS estimate?
WuXi XDC Cayman, Inc.’s EPS estimate is 0.91.
How many shares outstanding does WuXi XDC Cayman, Inc. have?
WuXi XDC Cayman, Inc. has 1,268,295,800 shares outstanding.
What happened to WuXi XDC Cayman, Inc.’s price movement after its last earnings report?
WuXi XDC Cayman, Inc. reported an EPS of HK$0.701 in its last earnings report, missing expectations of HK$0.806. Following the earnings report the stock price went down -2.582%.
Which hedge fund is a major shareholder of WuXi XDC Cayman, Inc.?
Currently, no hedge funds are holding shares in HK:2268
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
WuXi XDC Cayman, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
54.20%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
WuXi XDC Cayman, Inc.
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
2268 Stock 12 Month Forecast
Average Price Target
HK$91.06
▲(20.60% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―